Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential

$SBEV announces licensing agreement with Argent BioPharma for CannEpil®, a proprietary, cannabinoid-based therapeutic for the treatment of epilepsy (DRE)

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.